Login Register Cart 0
Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Therapeutic Strategies for the Management of Benzodiazepine (BZD) Withdrawal Syndrome: A Review

Author(s): Sangita Saini, Sumit Tahlan and Neha Minocha*

Volume 24, Issue 18, 2024

Published on: 10 May, 2024

Page: [1529 - 1541] Pages: 13

DOI: 10.2174/0115680266296096240408032738

Price: $65

Abstract

Benzodiazepines are commonly prescribed drugs for numerous indications such as epilepsy, anti-anxiety, sleep aids, sedatives, and hypnotics. Although the well-tolerated effects of benzodiazepine are seen in many clinical instances, the severity of side effects reduces its quantifiable use. Benzodiazepines, which are medically useful but theoretically unsafe, are frequently recommended by medical practitioners for psychotic patients but have misuse and dependence liabilities. It is impelled as a debateable topic globally about which no one talks. These drugs are also known as silent killers because abruptly stopping them can result in tremors, muscle spasticity, and life-frightening seizures. These drugs are beneficial as well as risky. Nonclinical treatment is simple and well suited and provides support for patients suffering from side effects generated by benzodiazepine withdrawal. This review mainly focuses on antipsychotic drugs and their mechanisms, mortality, withdrawal, abuse, and management via clinical and nonclinical therapies.

Next »
Graphical Abstract

[1]
Lalive, A.L.; Rudolph, U.; Lüscher, C.; Tan, K.R. Is there a way to curb benzodiazepine addiction? Swiss Med. Wkly., 2011, 141(4142), w13277.
[http://dx.doi.org/10.4414/smw.2011.13277] [PMID: 22012428]
[2]
Agarwal, S.D.; Landon, B.E. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw. Open, 2019, 2(1), e187399.
[http://dx.doi.org/10.1001/jamanetworkopen.2018.7399] [PMID: 30681713]
[3]
Howard, P.; Twycross, R.; Shuster, J.; Mihalyo, M.; Wilcock, A. Benzodiazepines. J. Pain Symptom Manage., 2014, 47(5), 955-964.
[http://dx.doi.org/10.1016/j.jpainsymman.2014.03.001] [PMID: 24681184]
[4]
Cascade, E.; Kalali, A.H. Use of benzodiazepines in the treatment of anxiety. Psychiatry (Edgmont), 2008, 5(9), 21-22.
[PMID: 19727256]
[5]
Dièye, A.M.; Sylla, M.; Ndiaye, A.; Ndiaye, M.; Guata Yoro, S.; Faye, B. Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists. Fundam. Clin. Pharmacol., 2006, 20(3), 235-238.
[http://dx.doi.org/10.1111/j.1472-8206.2006.00400.x] [PMID: 16671957]
[6]
Richardson, K.; Mattishent, K.; Loke, Y.K.; Steel, N.; Fox, C.; Grossi, C.M.; Bennett, K.; Maidment, I.; Boustani, M.; Matthews, F.E.; Myint, P.K.; Campbell, N.L.; Brayne, C.; Robinson, L.; Savva, G.M. History of benzodiazepine prescriptions and risk of dementia: possible bias due to prevalent users and covariate measurement timing in a nested case-control study. Am. J. Epidemiol., 2019, 188(7), 1228-1236.
[http://dx.doi.org/10.1093/aje/kwz073] [PMID: 31111865]
[7]
Kleinman, R.A.; Weiss, R.D. Benzodiazepine-involved overdose deaths in the USA: 2000–2019. J. Gen. Intern. Med., 2022, 37(8), 2103-2109.
[http://dx.doi.org/10.1007/s11606-021-07035-6] [PMID: 35415793]
[8]
Sung, H.G.; Li, J.; Nam, J.H.; Won, D.Y.; Choi, B.; Shin, J.Y. Concurrent use of benzodiazepines, antidepressants, and opioid analgesics with zolpidem and risk for suicide: a case–control and case–crossover study. Soc. Psychiatry Psychiatr. Epidemiol., 2019, 54(12), 1535-1544.
[http://dx.doi.org/10.1007/s00127-019-01713-x] [PMID: 31037540]
[9]
Teverovsky, E.G.; Gildengers, A.; Ran, X.; Jacobsen, E.; Chang, C.C.; Ganguli, M. Benzodiazepine use and risk of incident MCI and dementia in a community sample. Int. Psychogeriatr., 2023, 36(2), 1-7.
[PMID: 37231775]
[10]
Votaw, V.R.; Geyer, R.; Rieselbach, M.M.; McHugh, R.K. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend., 2019, 200, 95-114.
[http://dx.doi.org/10.1016/j.drugalcdep.2019.02.033] [PMID: 31121495]
[11]
Griffin, C.E., III; Kaye, A.M.; Bueno, F.R.; Kaye, A.D. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J., 2013, 13(2), 214-223.
[PMID: 23789008]
[12]
Jobert, A.; Laforgue, E.J.; Grall-Bronnec, M.; Rousselet, M.; Péré, M.; Jolliet, P.; Barjoux, C.; Batisse, A.; Boucher, A.; Caous, A-S.; Daveluy, A.; Eiden, C.; Fournier-Choma, C.; Frauger, E.; Gibaja, V.; Guerlais, M.; Jouanjus, E.; Le Boisselier, R.; Pain, S.; Feuillet, F.; Victorri-Vigneau, C. FAN-Network. Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur. J. Clin. Pharmacol., 2021, 77(2), 171-177.
[http://dx.doi.org/10.1007/s00228-020-03007-7] [PMID: 33006626]
[13]
MacDonald, T.; Gallo, A.T.; Basso-Hulse, G.; Bennett, K.S.; Hulse, G.K. A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept. Drug Alcohol Depend., 2022, 236, 109501.
[http://dx.doi.org/10.1016/j.drugalcdep.2022.109501] [PMID: 35644071]
[14]
Edinoff, A.N.; Nix, C.A.; Hollier, J.; Sagrera, C.E.; Delacroix, B.M.; Abubakar, T.; Cornett, E.M.; Kaye, A.M.; Kaye, A.D. Benzodiazepines: uses, dangers, and clinical considerations. Neurol. Int., 2021, 13(4), 594-607.
[http://dx.doi.org/10.3390/neurolint13040059] [PMID: 34842811]
[15]
Maust, D.T.; Petzold, K.; Strominger, J.; Kim, H.M.; Bohnert, A.S.B. Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy. JAMA Netw. Open, 2023, 6(12), e2348557.
[http://dx.doi.org/10.1001/jamanetworkopen.2023.48557] [PMID: 38117495]
[16]
Patorno, E.; Glynn, R.J.; Levin, R.; Lee, M.P.; Huybrechts, K.F. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ, 2017, 358, j2941.
[http://dx.doi.org/10.1136/bmj.j2941] [PMID: 28684397]
[17]
Fluyau, D.; Revadigar, N.; Manobianco, B.E. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther. Adv. Psychopharmacol., 2018, 8(5), 147-168.
[http://dx.doi.org/10.1177/2045125317753340] [PMID: 29713452]
[18]
Dodds, T.J. Prescribed benzodiazepines and suicide risk: a review of the literature. Prim. Care Companion CNS Disord., 2017, 19(2), 22746.
[http://dx.doi.org/10.4088/PCC.16r02037] [PMID: 28257172]
[19]
Rothschild, A.J.; Shindul-Rothschild, J.A. Benzodiazepines do not cause suicide or suicide attempts. Prim. Care Companion CNS Disord., 2017, 19(5), 26700.
[http://dx.doi.org/10.4088/PCC.17lr02171] [PMID: 29022652]
[20]
Henderson, A.; Wright, M.; Pond, S.M. Experience with 732 acute overdose patients admitted to an intensive care unit over six years. Med. J. Aust., 1993, 158(1), 28-30.
[http://dx.doi.org/10.5694/j.1326-5377.1993.tb121644.x] [PMID: 8417286]
[21]
Schmitz, A. Benzodiazepine use, misuse, and abuse: A review. Ment. Health Clin., 2016, 6(3), 120-126.
[http://dx.doi.org/10.9740/mhc.2016.05.120] [PMID: 29955458]
[22]
el-Guebaly, N.; Sareen, J.; Stein, M.B. Are there guidelines for the responsible prescription of benzodiazepines? Can. J. Psychiatry, 2010, 55(11), 709-714.
[http://dx.doi.org/10.1177/070674371005501104] [PMID: 21070698]
[23]
Soumerai, S.B.; Simoni-Wastila, L.; Singer, C.; Mah, C.; Gao, X.; Salzman, C.; Ross-Degnan, D. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr. Serv., 2003, 54(7), 1006-1011.
[http://dx.doi.org/10.1176/appi.ps.54.7.1006] [PMID: 12851438]
[24]
Kroll, D.S.; Nieva, H.R.; Barsky, A.J.; Linder, J.A. Benzodiazepines are prescribed more frequently to patients already at risk for benzodiazepine-related adverse events in primary care. J. Gen. Intern. Med., 2016, 31(9), 1027-1034.
[http://dx.doi.org/10.1007/s11606-016-3740-0] [PMID: 27177914]
[25]
Bandelow, B.; Michaelis, S.; Wedekind, D. Treatment of anxiety disorders. Dialogues Clin. Neurosci., 2017, 19(2), 93-107.
[http://dx.doi.org/10.31887/DCNS.2017.19.2/bbandelow] [PMID: 28867934]
[26]
Thibaut, F. Anxiety disorders: a review of current literature. Dialogues Clin. Neurosci., 2017, 19(2), 87-88.
[http://dx.doi.org/10.31887/DCNS.2017.19.2/fthibaut] [PMID: 28867933]
[27]
Bushnell, G.A.; Gerhard, T.; Crystal, S.; Olfson, M. Benzodiazepine treatment and fracture risk in young persons with anxiety disorders. Pediatrics, 2020, 146(1), e20193478.
[http://dx.doi.org/10.1542/peds.2019-3478] [PMID: 32499386]
[28]
Uzun, S.; Kozumplik, O.; Jakovljević, M.; Sedić, B. Side effects of treatment with benzodiazepines. Psychiatr. Danub., 2010, 22(1), 90-93.
[PMID: 20305598]
[29]
Rintoul, A.C.; Dobbin, M.D.H.; Nielsen, S.; Degenhardt, L.; Drummer, O.H. Recent increase in detection of alprazolam in Victorian heroin-related deaths. Med. J. Aust., 2013, 198(4), 206-209.
[http://dx.doi.org/10.5694/mja12.10986] [PMID: 23451965]
[30]
Ait-Daoud, N.; Hamby, A.S.; Sharma, S.; Blevins, D. A review of alprazolam use, misuse, and withdrawal. J. Addict. Med., 2018, 12(1), 4-10.
[http://dx.doi.org/10.1097/ADM.0000000000000350] [PMID: 28777203]
[31]
Lann, M.A.; Molina, D.K. A fatal case of benzodiazepine withdrawal. Am. J. Forensic Med. Pathol., 2009, 30(2), 177-179.
[http://dx.doi.org/10.1097/PAF.0b013e3181875aa0] [PMID: 19465812]
[32]
Breier, A.; Charney, D.S.; Nelson, J.C. Seizures induced by abrupt discontinuation of alprazolam. Am. J. Psychiatry, 1984, 141(12), 1606-1607.
[http://dx.doi.org/10.1176/ajp.141.12.1606] [PMID: 6150649]
[33]
Fialip, J.; Aumaitre, O.; Eschalier, A.; Maradeix, B.; Dordain, G.; Lavarenne, J. Benzodiazepine withdrawal seizures: analysis of 48 case reports. Clin. Neuropharmacol., 1987, 10(6), 538-544.
[http://dx.doi.org/10.1097/00002826-198712000-00005] [PMID: 3427560]
[34]
Wolf, B.; Grohmann, R.; Biber, D.; Brenner, P.; Rüther, E. Benzodiazepine abuse and dependence in psychiatric inpatients. Pharmacopsychiatry, 1989, 22(2), 54-60.
[http://dx.doi.org/10.1055/s-2007-1014578] [PMID: 2566180]
[35]
Conway, A.; Rolley, J.; Sutherland, J. R. Midazolam for sedation before procedures. Cochrane Database of Systematic Reviews, 2016, (5), CD009491.
[http://dx.doi.org/10.1002/14651858.CD009491.pub2] [PMID: 27198122]
[36]
Basit, H.; Kahwaji, C.I. Clonazepam. In: StatPearls; Treasure Island (FL), 2021.
[37]
Ahwazi, H.H.; Abdijadid, S. Chlordiazepoxide. In: StatPearls; Treasure Island (FL), 2021.
[38]
Humayun, M.J.; Samanta, D.; Carson, R.P. Clobazam. In: StatPearls; Treasure Island (FL), 2021.
[39]
Calcaterra, N.E.; Barrow, J.C. Classics in chemical neuroscience: Diazepam (valium). ACS Chem. Neurosci., 2014, 5(4), 253-260.
[http://dx.doi.org/10.1021/cn5000056] [PMID: 24552479]
[40]
Singh, R.; Abdijadid, S. Oxazepam. In: StatPearls; Treasure Island (FL), 2021.
[41]
Ghiasi, N.; Bhansali, R.K.; Marwaha, R. Lorazepam. In: StatPearls; Treasure Island (FL), 2021.
[42]
Chapoutot, M.; Peter-Derex, L.; Bastuji, H.; Leslie, W.; Schoendorff, B.; Heinzer, R.; Siclari, F.; Nicolas, A.; Lemoine, P.; Higgins, S.; Bourgeois, A.; Vallet, G.T.; Anders, R.; Ounnoughene, M.; Spencer, J.; Meloni, F.; Putois, B. Cognitive behavioral therapy and acceptance and commitment therapy for the discontinuation of long-term benzodiazepine use in insomnia and anxiety disorders. Int. J. Environ. Res. Public Health, 2021, 18(19), 10222.
[http://dx.doi.org/10.3390/ijerph181910222] [PMID: 34639523]
[43]
Brett, J.; Murnion, B. Management of benzodiazepine misuse and dependence. Aust. Prescr., 2015, 38(5), 152-155.
[http://dx.doi.org/10.18773/austprescr.2015.055] [PMID: 26648651]
[44]
Steenen, S.A.; van Wijk, A.J.; van der Heijden, G.J.M.G.; van Westrhenen, R.; de Lange, J.; de Jongh, A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J. Psychopharmacol., 2016, 30(2), 128-139.
[http://dx.doi.org/10.1177/0269881115612236] [PMID: 26487439]
[45]
Hoehn-Saric, R.; Merchant, A.F.; Keyser, M.L.; Smith, V.K. Effects of clonidine on anxiety disorders. Arch. Gen. Psychiatry, 1981, 38(11), 1278-1282.
[http://dx.doi.org/10.1001/archpsyc.1981.01780360094011] [PMID: 7305609]
[46]
Chiu, S.; Campbell, K. Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines; Canadian Agency for Drugs and Technologies in Health: Ottawa (ON), 2018.
[PMID: 30303668]
[47]
Goodman, W.K.; Charney, D.S.; Price, L.H.; Woods, S.W.; Heninger, G.R. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: Report of three cases. Am. J. Psychiatry, 1986, 143(7), 900-903.
[http://dx.doi.org/10.1176/ajp.143.7.900] [PMID: 2872826]
[48]
Schweizer, E.; Case, W.G.; Garcia-Espana, F.; Rickels, K.; Greenblatt, D.J. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal severity and taper outcome. Psychopharmacology, 1995, 117(4), 424-429.
[http://dx.doi.org/10.1007/BF02246214] [PMID: 7604143]
[49]
Hood, S.D.; Norman, A.; Hince, D.A.; Melichar, J.K.; Hulse, G.K. Benzodiazepine dependence and its treatment with low dose flumazenil. Br. J. Clin. Pharmacol., 2014, 77(2), 285-294.
[http://dx.doi.org/10.1111/bcp.12023] [PMID: 23126253]
[50]
Shukla, L.; Kandasamy, A.; Kesavan, M.; Benegal, V. Baclofen in the short-term maintenance treatment of benzodiazepine dependence. J. Neurosci. Rur. Pract., 2014, 5(S 01), S053-S054.
[http://dx.doi.org/10.4103/0976-3147.145203]
[51]
Rickels, K.; Schweizer, E.; García España, F.; Case, G.; DeMartinis, N.; Greenblatt, D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: Effects on withdrawal symptoms and taper outcome. Psychopharmacology, 1999, 141(1), 1-5.
[http://dx.doi.org/10.1007/s002130050798] [PMID: 9952057]
[52]
Pavlovic, Z.M. Long-term treatment and relapse prevention of alcohol and benzodiazepine dependence with lamotrigine. J. Neuropsychiatry Clin. Neurosci., 2010, 22(2), 247.e25-247.e26.
[http://dx.doi.org/10.1176/jnp.2010.22.2.247.e25] [PMID: 20463137]
[53]
Mariani, J.J.; Malcolm, R.J.; Mamczur, A.K.; Choi, J.C.; Brady, R.; Nunes, E.; Levin, F.R. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. Am. J. Drug Alcohol Abuse, 2016, 42(3), 333-340.
[http://dx.doi.org/10.3109/00952990.2015.1125493] [PMID: 26962719]
[54]
Tyrer, P.; Ferguson, B.; Hallström, C.; Michie, M.; Tyrer, S.; Cooper, S.; Caplan, R.; Barczak, P. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br. J. Psychiatry, 1996, 168(4), 457-461.
[http://dx.doi.org/10.1192/bjp.168.4.457] [PMID: 8730942]
[55]
Wright, A.; Diebold, J.; Otal, J.; Stoneman, C.; Wong, J.; Wallace, C.; Duffett, M. The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to discontinue benzodiazepines: A systematic review and meta-analysis. Drugs Aging, 2015, 32(12), 1009-1018.
[http://dx.doi.org/10.1007/s40266-015-0322-5] [PMID: 26547856]
[56]
Kawasaki, S.S.; Jacapraro, J.S.; Rastegar, D.A. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J. Subst. Abuse Treat., 2012, 43(3), 331-334.
[http://dx.doi.org/10.1016/j.jsat.2011.12.011] [PMID: 22285834]
[57]
Prather, P.L.; Rezazadeh, S.M.; Lane, J.D.; Rowan, G.A.; Hooper, M.L.; Lytle, D.A.; Emmett-Oglesby, M.W.; Lal, H. Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. J. Pharmacol. Exp. Ther., 1993, 264(2), 622-630.
[PMID: 8094750]
[58]
Romach, M.K.; Kaplan, H.L.; Busto, U.E.; Somer, G.; Sellers, E.M. A controlled trial of ondansetron, a 5-HT3 antagonist, in benzodiazepine discontinuation. J. Clin. Psychopharmacol., 1998, 18(2), 121-131.
[http://dx.doi.org/10.1097/00004714-199804000-00004] [PMID: 9555597]
[59]
Oulis, P.; Masdrakis, V.G.; Karapoulios, E.; Karakatsanis, N.A.; Kouzoupis, A.V.; Papadimitriou, G.N. For publication: Tiagabine in the discontinuation of long-term benzodiazepine use. Psychiatry Clin. Neurosci., 2009, 63(1), 122.
[http://dx.doi.org/10.1111/j.1440-1819.2008.01890.x] [PMID: 19154218]
[60]
Cheseaux, M.; Monnat, M.; Zullino, D.F. Topiramate in benzodiazepine withdrawal. Hum. Psychopharmacol., 2003, 18(5), 375-377.
[http://dx.doi.org/10.1002/hup.497] [PMID: 12858324]
[61]
Michopoulos, I.; Douzenis, A.; Christodoulou, C.; Lykouras, L. Topiramate use in alprazolam addiction. World J. Biol. Psychiatry, 2006, 7(4), 265-267.
[http://dx.doi.org/10.1080/15622970600671036] [PMID: 17071548]
[62]
Schulz, P.; Hede, V. Alternative and complementary approaches in psychiatry: beliefs versus evidence. Dialogues Clin. Neurosci., 2018, 20(3), 207-214.
[http://dx.doi.org/10.31887/DCNS.2018.20.3/pschulz] [PMID: 30581290]
[63]
Butler, A.; Chapman, J.; Forman, E.; Beck, A. The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clin. Psychol. Rev., 2006, 26(1), 17-31.
[http://dx.doi.org/10.1016/j.cpr.2005.07.003] [PMID: 16199119]
[64]
Sweetman, A.; Knieriemen, A.; Hoon, E.; Frank, O.; Stocks, N.; Natsky, A.; Kaambwa, B.; Vakulin, A.; Lovato, N.; Adams, R.; Lack, L.; Miller, C.B.; Espie, C.A.; McEvoy, R.D. Implementation of a digital cognitive behavioral therapy for insomnia pathway in primary care. Contemp. Clin. Trials, 2021, 107, 106484.
[http://dx.doi.org/10.1016/j.cct.2021.106484] [PMID: 34129952]
[65]
Sweetman, A.; Putland, S.; Lack, L.; McEvoy, R.D.; Adams, R.; Grunstein, R.; Stocks, N.; Kaambwa, B.; Van Ryswyk, E.; Gordon, C.; Vakulin, A.; Lovato, N. The effect of cognitive behavioural therapy for insomnia on sedative-hypnotic use: A narrative review. Sleep Med. Rev., 2021, 56, 101404.
[http://dx.doi.org/10.1016/j.smrv.2020.101404] [PMID: 33370637]
[66]
Sampathi, B.R. Asian mental health and use of drama therapy for acculturative family distancing in immigrant families. Ment. Illn., 2018, 10(2), 35.
[http://dx.doi.org/10.1108/mi.2018.7806] [PMID: 30542524]
[67]
Chang, W.L.; Liu, Y.S.; Yang, C.F. Drama therapy counseling as mental health care of college students. Int. J. Environ. Res. Public Health, 2019, 16(19), 3560.
[http://dx.doi.org/10.3390/ijerph16193560] [PMID: 31547613]
[68]
Petrovsky, D.; Cacchione, P.Z.; George, M. Review of the effect of music interventions on symptoms of anxiety and depression in older adults with mild dementia. Int. Psychogeriatr., 2015, 27(10), 1661-1670.
[http://dx.doi.org/10.1017/S1041610215000393] [PMID: 25921299]
[69]
Witusik, A.; Pietras, T. Music therapy as a complementary form of therapy for mental disorders. Pol. Merkuriusz Lek., 2019, 47(282), 240-243.
[PMID: 31945027]
[70]
Rusowicz, J.; Szczepańska-Gieracha, J.; Kiper, P. Neurologic Music Therapy in Geriatric Rehabilitation: A Systematic Review. Healthcare, 2022, 10(11), 2187.
[http://dx.doi.org/10.3390/healthcare10112187] [PMID: 36360527]
[71]
Geretsegger, M.; Mössler, K. A.; Bieleninik, Ł.; Chen, X. J.; Heldal, T. O.; Gold, C. Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database of Systematic Reviews, 2017, 5
[http://dx.doi.org/10.1002/14651858.CD004025.pub4]
[72]
Iguina, M.M.; Kashan, S. Art Therapy. In: StatPearls; Treasure Island (FL), 2022.
[73]
Hu, J.; Zhang, J.; Hu, L.; Yu, H.; Xu, J. Art therapy: a complementary treatment for mental disorders. Front. Psychol., 2021, 12, 686005.
[http://dx.doi.org/10.3389/fpsyg.2021.686005] [PMID: 34456801]
[74]
Veronese, N.; Maggi, S.; Schofield, P.; Stubbs, B. Dance movement therapy and falls prevention. Maturitas, 2017, 102, 1-5.
[http://dx.doi.org/10.1016/j.maturitas.2017.05.004] [PMID: 28610676]
[75]
Meekums, B.; Karkou, V.; Nelson, E. A. Dance movement therapy for depression. Cochrane Database of Systematic Reviews, 2015, 2
[http://dx.doi.org/10.1002/14651858.CD009895.pub2]
[76]
Bradt, J.; Shim, M.; Goodill, S. W. Dance/movement therapy for improving psychological and physical outcomes in cancer patients. Cochrane Database of Systematic Reviews, 2015, (1)
[77]
Miralles, I.; Granell, C.; Díaz-Sanahuja, L.; Van Woensel, W.; Bretón-López, J.; Mira, A.; Castilla, D.; Casteleyn, S. Smartphone apps for the treatment of mental disorders: systematic review. JMIR Mhealth Uhealth, 2020, 8(4), e14897.
[http://dx.doi.org/10.2196/14897] [PMID: 32238332]
[78]
Horsch, C.H.G.; Lancee, J.; Griffioen-Both, F.; Spruit, S.; Fitrianie, S.; Neerincx, M.A.; Beun, R.J.; Brinkman, W.P. Mobile phone-delivered cognitive behavioral therapy for insomnia: a randomized waitlist controlled trial. J. Med. Internet Res., 2017, 19(4), e70.
[http://dx.doi.org/10.2196/jmir.6524] [PMID: 28400355]
[79]
Sarris, J.; Murphy, J.; Mischoulon, D.; Papakostas, G.I.; Fava, M.; Berk, M.; Ng, C.H. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Focus Am. Psychiatr. Publ., 2018, 16(3), 328-340.
[http://dx.doi.org/10.1176/appi.focus.16304] [PMID: 32015713]
[80]
Businaro, R.; Vauzour, D.; Sarris, J.; Münch, G.; Gyengesi, E.; Brogelli, L.; Zuzarte, P. Therapeutic opportunities for food supplements in neurodegenerative disease and depression. Front. Nutr., 2021, 8, 669846.
[http://dx.doi.org/10.3389/fnut.2021.669846] [PMID: 34055858]
[81]
Uebaba, K.; Xu, F.H.; Ogawa, H.; Tatsuse, T.; Wang, B.H.; Hisajima, T.; Venkatraman, S. Psychoneuroimmunologic effects of Ayurvedic oil-dripping treatment. J. Altern. Complement. Med., 2008, 14(10), 1189-1198.
[http://dx.doi.org/10.1089/acm.2008.0273] [PMID: 19123874]
[82]
Tokinobu, A.; Yorifuji, T.; Tsuda, T.; Doi, H. Effects of ayurvedic oil-dripping treatment with sesame oil vs. with warm water on sleep: a randomized single-blinded crossover pilot study. J. Altern. Complement. Med., 2016, 22(1), 52-58.
[http://dx.doi.org/10.1089/acm.2015.0018] [PMID: 26669255]
[83]
Bhinde, S. A case study on the Ayurvedic management of cerebral palsy. Anc. Sci. Life, 2015, 34(3), 167-170.
[http://dx.doi.org/10.4103/0257-7941.157163] [PMID: 26120232]
[84]
Jindal, N.; Shamkuwar, M.; Kaur, J.; Berry, S. Efficacy of Āyurvedictreatment using Pancakarma combined with balance exercises for disability and balance in progressive supranuclear palsy. Anc. Sci. Life, 2012, 32(1), 54-58.
[http://dx.doi.org/10.4103/0257-7941.113793] [PMID: 23929996]
[85]
Tubaki, B.R.; Chandake, S.; Sarhyal, A. Ayurveda management of Major Depressive Disorder: A case study. J. Ayurveda Integr. Med., 2021, 12(2), 378-383.
[http://dx.doi.org/10.1016/j.jaim.2021.03.012] [PMID: 34024690]
[86]
Legg, L. A.; Lewis, S. R.; Schofield-Robinson, O. J.; Drummond, A.; Langhorne, P. Occupational therapy for adults with problems in activities of daily living after stroke. Cochrane Database of Systematic Reviews, 2017. 7.
[http://dx.doi.org/10.1161/STROKEAHA.117.018923]
[87]
Bennett, S.; Laver, K.; Voigt-Radloff, S.; Letts, L.; Clemson, L.; Graff, M.; Wiseman, J.; Gitlin, L. Occupational therapy for people with dementia and their family carers provided at home: a systematic review and meta-analysis. BMJ Open, 2019, 9(11), e026308.
[http://dx.doi.org/10.1136/bmjopen-2018-026308] [PMID: 31719067]
[88]
Saeed, S.A.; Antonacci, D.J.; Bloch, R.M. Exercise, yoga, and meditation for depressive and anxiety disorders. Am. Fam. Physician, 2010, 81(8), 981-986.
[PMID: 20387774]
[89]
Saeed, S.A.; Cunningham, K.; Bloch, R.M. Depression and anxiety disorders: benefits of exercise, yoga, and meditation. Am. Fam. Physician, 2019, 99(10), 620-627.
[PMID: 31083878]
[90]
Krishnakumar, D.; Hamblin, M.R.; Lakshmanan, S. Meditation and yoga can modulate brain mechanisms that affect behavior and anxiety - A modern scientific perspective. Anc. Sci., 2015, 2(1), 13-19.
[http://dx.doi.org/10.14259/as.v2i1.171] [PMID: 26929928]
[91]
Setzer, W.N. Essential oils and anxiolytic aromatherapy. Nat. Prod. Commun., 2009, 4(9), 1934578X0900400.
[http://dx.doi.org/10.1177/1934578X0900400928] [PMID: 19831048]
[92]
Ebrahimi, H.; Mardani, A.; Basirinezhad, M.H.; Hamidzadeh, A.; Eskandari, F. The effects of Lavender and Chamomile essential oil inhalation aromatherapy on depression, anxiety and stress in older community-dwelling people: A randomized controlled trial. Explore (NY), 2022, 18(3), 272-278.
[http://dx.doi.org/10.1016/j.explore.2020.12.012] [PMID: 33454232]
[93]
Sánchez-Vidaña, D.I.; Ngai, S.P.C.; He, W.; Chow, J.K.W.; Lau, B.W.M.; Tsang, H.W.H. The effectiveness of aromatherapy for depressive symptoms: A systematic review. Evid. Based Complement. Alternat. Med., 2017, 2017, 1-21.
[http://dx.doi.org/10.1155/2017/5869315] [PMID: 28133489]
[94]
De Maricourt, P.; Gorwood, P.; Hergueta, T.; Galinowski, A.; Salamon, R.; Diallo, A.; Vaugeois, C.; Lépine, J.P.; Olié, J.P.; Dubois, O. Balneotherapy together with a psychoeducation program for benzodiazepine withdrawal: a feasibility study. Evid. Based Complement. Alternat. Med., 2016, 2016, 1-7.
[http://dx.doi.org/10.1155/2016/8961709] [PMID: 27956923]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy